Abstract
Background: Chronic cardiac dysfunction may develop after administration of aggressive chemotherapy, sometimes leading to development of congestive heart failure (CHF). Recently, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was implicated as a marker of CHF. In this study we evaluated the predictive role of NT-proBNP in patients treated with high-dose chemotherapy (HDC). Methods: NT-proBNP was measured after 62 chemotherapy treatments in 52 patients affected by aggressive malignancies. Blood samples were drawn before the start of HDC, at the end of HDC administration, and 12, 24, 36, and 72 h thereafter. In these patients, echocardiograms were performed regularly during a 1-year follow-up. Results: Seventeen patients (33%) had persistently increased NT-proBNP, 19 patients (36%) had only transient increases (concentrations went back to baseline at 72 h), and 16 (31%) had no increases [mean (SD) values at 72 h, 1163 (936) ng/L vs 185 (101) ng/L vs 39 (19) ng/L, respectively; P
| Original language | English |
|---|---|
| Pages (from-to) | 1405-1410 |
| Number of pages | 6 |
| Journal | Clinical Chemistry |
| Volume | 51 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2005 |
Fingerprint
ASJC Scopus subject areas
- Clinical Biochemistry
Cite this
N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy : A marker predictive of cardiac dysfunction? / Sandri, Maria T.; Salvatici, Michela; Cardinale, Daniela; Zorzino, Laura; Passerini, Rita; Lentati, Paola; Leon, Maria; Civelli, Maurizio; Martinelli, Giovanni; Cipolla, Carlo M.
In: Clinical Chemistry, Vol. 51, No. 8, 08.2005, p. 1405-1410.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy
T2 - A marker predictive of cardiac dysfunction?
AU - Sandri, Maria T.
AU - Salvatici, Michela
AU - Cardinale, Daniela
AU - Zorzino, Laura
AU - Passerini, Rita
AU - Lentati, Paola
AU - Leon, Maria
AU - Civelli, Maurizio
AU - Martinelli, Giovanni
AU - Cipolla, Carlo M.
PY - 2005/8
Y1 - 2005/8
N2 - Background: Chronic cardiac dysfunction may develop after administration of aggressive chemotherapy, sometimes leading to development of congestive heart failure (CHF). Recently, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was implicated as a marker of CHF. In this study we evaluated the predictive role of NT-proBNP in patients treated with high-dose chemotherapy (HDC). Methods: NT-proBNP was measured after 62 chemotherapy treatments in 52 patients affected by aggressive malignancies. Blood samples were drawn before the start of HDC, at the end of HDC administration, and 12, 24, 36, and 72 h thereafter. In these patients, echocardiograms were performed regularly during a 1-year follow-up. Results: Seventeen patients (33%) had persistently increased NT-proBNP, 19 patients (36%) had only transient increases (concentrations went back to baseline at 72 h), and 16 (31%) had no increases [mean (SD) values at 72 h, 1163 (936) ng/L vs 185 (101) ng/L vs 39 (19) ng/L, respectively; P
AB - Background: Chronic cardiac dysfunction may develop after administration of aggressive chemotherapy, sometimes leading to development of congestive heart failure (CHF). Recently, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was implicated as a marker of CHF. In this study we evaluated the predictive role of NT-proBNP in patients treated with high-dose chemotherapy (HDC). Methods: NT-proBNP was measured after 62 chemotherapy treatments in 52 patients affected by aggressive malignancies. Blood samples were drawn before the start of HDC, at the end of HDC administration, and 12, 24, 36, and 72 h thereafter. In these patients, echocardiograms were performed regularly during a 1-year follow-up. Results: Seventeen patients (33%) had persistently increased NT-proBNP, 19 patients (36%) had only transient increases (concentrations went back to baseline at 72 h), and 16 (31%) had no increases [mean (SD) values at 72 h, 1163 (936) ng/L vs 185 (101) ng/L vs 39 (19) ng/L, respectively; P
UR - http://www.scopus.com/inward/record.url?scp=23044510968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23044510968&partnerID=8YFLogxK
U2 - 10.1373/clinchem.2005.050153
DO - 10.1373/clinchem.2005.050153
M3 - Article
C2 - 15932966
AN - SCOPUS:23044510968
VL - 51
SP - 1405
EP - 1410
JO - Clinical Chemistry
JF - Clinical Chemistry
SN - 0009-9147
IS - 8
ER -